Live Breaking News & Updates on Clinical oncology annual meeting

Stay informed with the latest breaking news from Clinical oncology annual meeting on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical oncology annual meeting and stay connected to the pulse of your community

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...

France , Madrid , Spain , Switzerland , Texas , United-states , Chicago , Illinois , Lugano , Ticino , Norway , Paris

Novartis Pharma AG: Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Novartis Pharma AG: Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland , Texas , United-states , Lugano , Ticino , Madrid , Spain , Paris , France-general- , France , Chicago , Illinois

New Data Bring Excitement, Raise Questions in Advanced RCC

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

United-states , American , Eric-jonasch , Elizabeth-plimack , Briani-rini , Onclive-peer-exchange , American-society-of-clinical-oncology-annual-meeting , Clinical-oncology-annual-meeting , Frontline-advanced , Statpearls-publishing , News , Genitourinary-cancers

Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

United-kingdom , Houston , Texas , United-states , London , City-of , American , Neeta-somaiah , Robin-jones , Department-of-sarcoma-medical-oncology , American-society-of-clinical-oncology-annual-meeting , University-of-texas-md-anderson-cancer-center

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

United-states , American , Shuntaro-ikegawa , Dana-farber-cancer-institute , Dana-farber-institute , American-society-for-clinical-oncology-annual-meeting , Clinical-oncology-annual-meeting , Patients-with-relapsed-refractory-multiple-myeloma- , Multiple-myeloma , International-myeloma-society-annual-meeting , Phase-1-trial-nct04318327- , Durcabtagene-autoleucel-

Multidisciplinary Approaches Shape Treatment Pathways in EGFR-Mutated NSCLC

Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.

Chicago , Illinois , United-states , American , Gustavo-cumbo-nacheli , Ashish-saxena , Nicholas-rohs , Zofia-piotrowska , Onclive-peer-exchange , American-society-of-clinical-oncology-annual-meeting , Moon-lee , Wild-west

NY Lung Seeks to Bridge Gaps in Lung Cancer Decision-Making

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

New-york , United-states , American , Rasheda-persinger , Balazs-halmos , Megan-schollenberger , American-society-of-clinical-oncology-annual-meeting , European-society-for-medical-oncology-congress , Annual-new-york-lung-cancers-symposium , Clinical-oncology-annual-meeting , International-association , Lung-cancer

Amgen unveils Partners of Choice oncology network

Amgen Partners of Choice will comprise eight medical institutions worldwide, including the Dana-Farber Cancer Institute in Boston and Gustave Roussy in Paris.

Points-of-view , New-york , United-states , Boston , Massachusetts , Dana-farber-cancer-institute , Memorial-sloan-kettering-cancer-center , Paris , France-general- , France , Seoul , Soult-ukpyolsi

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.

United-states , American , Daiichi-sankyo , Ken-takeshita , Susan-galbraith , Astrazeneca , American-society-of-clinical-oncology-annual-meeting , Clinical-oncology-annual-meeting , Cancers-symposium , Fda , Colorectal , Cancer

Novartis : Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer -September 14, 2023 at 01:26 pm EDT

Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023.

European Society...

Spain , France , San-antonio , Texas , United-states , Switzerland , Lugano , Ticino , Paris , France-general- , Chicago , Illinois